TB Vaccine Candidate M72/AS01E Set for Production Ready to Prevent Millions of Cases
GS2Polity · Governance · IR· Health policy & public health· Prelims + Mains·
Why in news
The Gates Medical Research Institute partnered with Serum Institute of India (SII) to manufacture the M72/AS01E TB vaccine candidate following successful Phase 3 trials.
Background
The M72/AS01E vaccine candidate is currently in Phase 3 trials involving 20,000 participants across five countries. Serum Institute of India (SII) will invest over $100 million for production readiness, with GSK supplying the necessary adjuvant.
Facts for Prelims
- S&TM72/AS01E: A vaccine candidate specifically targeting Tuberculosis (TB).
- BodySerum Institute of India (SII): World's largest vaccine manufacturer based in Pune, Maharashtra.
- FactThe Phase 3 trial enrolled 20,000 participants across five countries.
- PostGates Medical Research Institute: A research entity funded by the Bill & Melinda Gates Foundation.
For Mains
Q. Discuss the significance of public-private partnerships in accelerating the development and manufacturing of vaccines for neglected tropical diseases and infectious diseases like Tuberculosis.
Dimensions to cover in your answer
- R&D bottleneck: High costs of Phase 3 clinical trials often deter private investment without philanthropic or public funding.
- Manufacturing scalability: Leveraging SII's production capacity to ensure global vaccine equity and affordable pricing.
- Adjuvant dependency: Risks associated with relying on third-party suppliers (like GSK) for critical vaccine components.
Keywords: Public-Private Partnership · Vaccine Equity · Clinical Trials · Infectious Disease Management · Biotechnology
More Social Justice notes
- Amid NEET paper leak protests in India, Vineet Joshi was replaced · 24 July 2026
- Modi announces fast-track courts for paper leak cases, talks resume with protest leaders · 23 July 2026
- Karnataka High Court Hears Petition to Declare ‘Spouse’ Term Unconstitutional in Tax Act · 23 July 2026
- Delhi High Court Calls Merck Vaccine Rollout "Very Serious Matter" · 23 July 2026
- Gujarat High Court: Scheduled Castes get lifetime reservation benefits, rejecting EPFO’s plea · 22 July 2026
- Karnataka FSDA Cracks Down: ₹28.91 Lakh Penalties for Trans Fat Violations · 22 July 2026
Something wrong, or something missing?
Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.
Report a mistake →Ask for something →thesatyadheesh@gmail.com
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.